Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Introduction

Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia.

Methods

We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety.

Results

Four RCTs with 369 schizophrenia patients were include

SUBMITTER: Kassar O 

PROVIDER: S-EPMC12581406 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature